{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:30:37Z","timestamp":1786995037428,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.nmd.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T05:23:21Z","timestamp":1711085001000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-7030","authenticated-orcid":false,"given":"Katherine C","family":"Dodd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James KL","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Isabel","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James AL","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyae Phyo","family":"San","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Viegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2024.03.010_bib0001","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.03.010_bib0002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"},{"key":"10.1016\/j.nmd.2024.03.010_bib0003","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2024.03.010_bib0004","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1196\/annals.1405.031","article-title":"Lessons from two trials of mycophenolate mofetil in myasthenia gravis","volume":"1132","author":"Sanders","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2024.03.010_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CND.0000000000000342","article-title":"Methotrexate as a steroid-sparing agent in myasthenia gravis: a preliminary retrospective study","volume":"23","author":"Rodolico","year":"2021","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2024.03.010_bib0006","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2024.03.010_bib0007","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.03.010_bib0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2024.03.010_bib0009","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.03.010_bib0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/pds.926","article-title":"Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease","volume":"13","author":"Gearry","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.nmd.2024.03.010_bib0011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CND.0000000000000133","article-title":"A review of azathioprine-associated hepatotoxicity and myelosuppression in myasthenia gravis","volume":"18","author":"Jack","year":"2016","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2024.03.010_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2024.03.010_bib0013","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2024.03.010_bib0014","unstructured":"Methotrexate 2.5 mg tablets - Summary of Product Characteristics (SmPC) - (emc) n.d. https:\/\/www.medicines.org.uk\/emc\/product\/511\/smpc (accessed April 4, 2023)."},{"key":"10.1016\/j.nmd.2024.03.010_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cen3.12495","article-title":"Clinical burden and healthcare resource utilization associated with myasthenia gravis: assessments from a Japanese claims database","volume":"10","author":"Murai","year":"2019","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.nmd.2024.03.010_bib0016","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2024.03.010_bib0017","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.nmd.2024.03.010_bib0018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jcag\/gwaa005","article-title":"Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel disease","volume":"4","author":"Wilson","year":"2021","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1016\/j.nmd.2024.03.010_bib0019","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s10620-022-07719-x","article-title":"Low-dose azathioprine in combination with allopurinol: the past, present and future of this useful duo","volume":"67","author":"Turbayne","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.nmd.2024.03.010_bib0021","doi-asserted-by":"crossref","first-page":"A624","DOI":"10.1016\/S0016-5085(01)83103-6","article-title":"Change in red cell mean corpuscular volume (MCV) during azathioprine or 6-MP therapy for Crohn's disease may indicate optimal dose titration","volume":"120","author":"Garza","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nmd.2024.03.010_bib0023","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/apt.13879","article-title":"Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease","volume":"45","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.nmd.2024.03.010_bib0026","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13555-019-00346-x","article-title":"A comparison of azathioprine and mycophenolate mofetil as adjuvant drugs in patients with Pemphigus: a retrospective cohort study","volume":"10","author":"Sukanjanapong","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.nmd.2024.03.010_bib0027","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.03.010_bib0028","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","article-title":"Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?","volume":"23","author":"Vasudevan","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nmd.2024.03.010_bib0030","doi-asserted-by":"crossref","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med"},{"key":"10.1016\/j.nmd.2024.03.010_bib0031","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MCG.0000000000000568","article-title":"Azathioprine and 6-mercaptopurine-induced liver injury: clinical features and outcomes","volume":"51","author":"Bj\u00f6rnsson","year":"2017","journal-title":"J Clin Gastroenterol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:41:49Z","timestamp":1714372909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":26,"alternative-id":["S0960896624000634"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.03.010","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}